Highest-materiality recent filing
Lifeward Q1 revenue down 22%, net loss widens to $10.8M; cash improves to $11.4M
Revenue $3.9M (down 22% YoY); AlterG sales fell 38% to $2.1M on supply chain timing.
Lifeward completes acquisition of Oratech Pharma, issues shares and convertible notes
Lifeward completed acquisition of Oratech Pharma on March 25, 2026, issuing 2,256,476 ordinary shares and pre-funded warrants to Oramed.
Lifeward receives Nasdaq notice for audit committee non-compliance after director resignation
Audit committee reduced to two members following Hadar Levy's board resignation.
Lifeward posts Q4 revenue $5.1M (-33% YoY); enters Oramed deal for oral insulin platform
Q4 revenue $5.1M (-33% YoY); full year $22.0M (-14% YoY). ReWalk exoskeleton sales +20% in Q4.
Lifeward shareholders approve Oratech Pharma acquisition and related proposals
Proposal 1 passed: issuance of ordinary shares to Oramed for Oratech acquisition (1,854,591 for, 470,084 against).
Lifeward completes 1-for-12 reverse stock split to regain Nasdaq compliance
18.34M shares consolidated to ~1.53M shares; authorized shares increased from 75M to 100M.
Lifeward enters $525K secured note with Oramed at 24% interest, expandable by $975K
Initial principal $525,000; mutual consent can increase by up to $975,000 for total up to $1.5M.
Lifeward gets 180-day Nasdaq bid-price extension to Aug 3, 2026; 1-for-12 reverse split approved
Nasdaq gave Lifeward 180-day extension until Aug 3, 2026 to meet $1.00 bid price rule.
Lifeward schedules March 12 meeting to vote on Oratech acquisition from Oramed; board to expand to 8
EGM on March 12, 2026 to approve issuance of shares to Oramed as consideration for acquiring all of Oratech.
Lifeward acquires Oramed's POD tech; Oramed gets up to 49.99% LFWD stake; up to $47M capital
Issues Oramed shares & pre-funded warrants for 49.99% fully diluted equity (max 45% post-closing).
Lifeward Q3 revenue $6.2M (+1% YoY); net loss $0.20/shr; secures $3M loan from Oramed
Revenue $6.2M (+1% YoY); traditional products up 24% to $3.1M; AlterG down 15% to $3.1M.
Lifeward reports preliminary Q3 revenue $6.2M, cash $2.0M
Preliminary Q3 2025 revenue approximately $6.2 million, unaudited.
Lifeward Q2 revenue $5.7M (-15% YoY); net loss $6.6M; resets 2025 guidance
Revenue $5.7M, down 15% YoY; traditional product revenue $2.5M (-19% YoY) excluding one-time Medicare benefit.
Lifeward appoints Almog Adar as CFO, effective August 1, 2025
Almog Adar, previously VP of Finance and CAO, named CFO effective August 1, 2025.
Lifeward receives Nasdaq bid price deficiency notice; shares face potential delisting
Received Nasdaq notice on Aug 5, 2025; closing bid below $1.00 for 30 consecutive business days.
Proposal 5 failed: 811,866 for vs 993,112 against (excluding 3.4M broker non-votes).
Lifeward closes $2.6M public offering of 4M shares and warrants
Offering of 4M units at $0.65/unit, each consisting of 1 ordinary share + 1 warrant.
Lifeward appoints Mark Grant as President and CEO, effective June 2, 2025
Mark Grant will become CEO on June 2; Larry Jasinski serves as Co-CEO through June 30, then advisory through 2025.
Larry Jasinski, a member of the Board and the Company’s Co-Chief Executive Officer, notified the Board of his decision to resign as a member of the Board, effective as of June 30, 2025.
appointed Mark Grant as a Class II director, effective June 15, 2025.
On June 2, 2025, Michael Lawless notified Lifeward Ltd. (the “ Company ”) of his resignation as Chief Financial Officer and Principal Financial Officer, effective as of June 27, 2025 or such earlier date as agreed upon by the Company and Mr. Lawless.
the Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) approved the appointment of Mark Grant as the Company’s President and Chief Executive Officer, effective June 2, 2025
Max materiality 0.90 · Median 0.62 · Most common event leadership